Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Microbiota Transplant in Acute Liver Failure
NCT03363022Withdrawn
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Feb 2020
- Primary completion
- Dec 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, double-blind trial in acute liver failure (ALF) comparing FMT Arm with Placebo Arm (2 arms). Primary endpoint: Survival in both groups at Day 21. Planned start Feb 2020; status: withdrawn.
02
Drugs
fecal microbiome transplant
03
Conditions
acute liver failure (ALF)
Beyond the preview
Go deeper on NCT03363022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363022.